Gold Standard Diagnostics Signs U.S. Distribution Agreement With Fujirebio Diagnostics, Inc. for Multi-Constituent Tumor Marker Control

Published: Jul 13, 2011

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics, Corp., (GSD) a leading supplier of products and services to the medical diagnostic industry, today announced the execution of an agreement with Fujirebio Diagnostics to distribute their proprietary Multi-Constituent Tumor Marker Control in the United States. Fujirebio Diagnostics, best known in the U.S. market as the developers of the CA125 ovarian cancer marker, has several patents on biomarkers for various disease states, but is primarily focused on oncology markers.

Back to news